Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 11 of 39, showing 5 Applications out of 192 total, starting on record 51, ending on 55

# Protocol No Study Title Investigator(s) & Site(s)

51.

ECCT/23/04/03   ACTIV-2d/A5407
    A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19   
Principal Investigator(s)
1. Prof Abraham Mosigisi Siika
Site(s) in Kenya
1. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
2. Victoria Biomedical Research Institute, (Kisumu county)
3. Kenyatta National Hospital (Nairobi City county)
4. KEMRI CCR – BUTERE SITE (Kakamega county)
5. Kenya Medical Research Institute/Walter Reed Project (Kericho county)
6. KEMRI – AHERO Clinical Trials Units (Kisumu county)
 
View

52.

ECCT/23/03/06   PDMC-II
    Dihydroartemisinin-piperaquine and azithromycin for the post-discharge management of children with severe anaemia in Malawi, Kenya and Uganda; A, multicentre, parallel-group, two-arm, randomised, double-blind superiority trial.   
Principal Investigator(s)
1. Simon Kariuki
2. Titus Kwambai
Site(s) in Kenya
Jaramogi Oginga Odinga Teaching and Referral Hospital
 
View

53.

ECCT/23/03/04   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Lucas Otieno Tina
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
 
View

54.

ECCT/23/03/05   SKY-06
    A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS   PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER   
Principal Investigator(s)
1. Dr Primus Ochieng
Site(s) in Kenya
1. University of Nairobi -Institute of Tropical and Infectious Diseases (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View

55.

ECCT/23/05/07   LATA
    Long-Acting Treatment in Adolescents (LATA) A randomised open-label 2-arm 96 week trial in virologically suppressed HIV-1-positive adolescents aged 12-19 years of age in Sub-Saharan Africa   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1.
 
View